Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom.
Jararhagin, a haemorrhagic metalloproteinase from Bothrops jararaca venom, plays an important role in systemic as well as local haemorrhage. In this study, the effect of jararhagin on the fibrinolytic system was investigated. The fibrinolytic activity of various kinds of animal plasmas was measured by the fibrin plate method. No activity was detected in plasma alone. However, after mixing plasma with jararhagin, strong fibrinolytic activity was recorded in guinea-pig, horse, dog, rabbit and human plasmas. The mechanism of the increase of firbinolytic activity by jararhagin was studied further in guinea-pig plasma. Fibrin-zymographic studies indicated that jararhagin increased tissue-type plasminogen activator (tPA) activity by the dissociation of a complex of tPA with type 1 plasminogen activator inhibitor (PAI-1). alpha 2-Plasmin inhibitor (alpha 2-PI) activity in the plasma was measured using a synthetic chromogenic substrate method after incubation with jararhagin. The alpha 2-PI activity in the plasma decreased in both time-dependent and dose-dependent manners. These in vitro results suggest that, in some animal plasmas, jararhagin increases plasma fibrinolytic activity by causing dissociation of the tPA/PAI-1 complex and by the inactivation of alpha 2-PI. It is possible that this direct action of jararhagin on the enhancement of plasma fibrinolytic activity may contribute to the aetiology of systemic haemorrhage frequently observed in human victims of B. jararaca envenoming.
Sugiki
M
M
Department of Physiology, Miyazaki Medical College, Japan.
Maruyama
M
M
Yoshida
E
E
Mihara
H
H
Kamiguti
A S
AS
Theakston
D G
DG
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D003435:Crotalid Venoms / Q000008:administration & dosage / Q000302:isolation & purification / Q000378:metabolism / Q000633:toxicity*; D004285:Dogs; D004591:Electrophoresis, Polyacrylamide Gel; D005342:Fibrinolysis / Q000187:drug effects*; D006168:Guinea Pigs; D006470:Hemorrhage / Q000139:chemically induced*; D006736:Horses; D006801:Humans; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000302:isolation & purification / Q000378:metabolism / Q000633:toxicity*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism / Q000633:toxicity; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D011817:Rabbits; D015842:Serine Proteinase Inhibitors / Q000378:metabolism / Q000633:toxicity*; D010959:Tissue Plasminogen Activator / Q000187:drug effects / Q000378:metabolism; D000979:alpha-2-Antiplasmin / Q000032:analysis / Q000378:metabolism; D000097146:Bothrops jararaca Venom
D001798:Blood Proteins; D003435:Crotalid Venoms; D008666:Metalloendopeptidases; D017395:Plasminogen Activator Inhibitor 1; D010975:Platelet Aggregation Inhibitors; D015842:Serine Proteinase Inhibitors; D010959:Tissue Plasminogen Activator; D000979:alpha-2-Antiplasmin; D000097146:Bothrops jararaca Venom